Journals / Acta Medica Nicomedia / 2026 / Cilt: 9

RELATIONSHIP BETWEEN FIBROSIS SCORES AND FERRITIN, VITAMIN D, AND MAGNESIUM IN TYPE 2 DIABETES–RELATED HEPATIC STEATOSIS

TİP 2 DİYABETE EŞLİK EDEN HEPATOSTEATOZDA FİBROZİS SKORLARI İLE FERRİTİN, D VİTAMİNİ VE MAGNEZYUM DÜZEYLERİ ARASINDAKİ İLİŞKİNİN DEĞERLENDİRİLMESİ

Gülşah Altun(Sivas Numune Hastanesi)0000-0001-5209-3569
Berçem Afşar Karatepe(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ELAZIĞ FETHİ SEKİN ŞEHİR SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0002-6772-8827
Pages
1–11
Publication Date
2026-07-29
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Ferritin and vitamin D were associated with fibrosis only in univariate analyses and were not independent predictors after demographic adjustment, suggesting they reflect underlying metabolic and age-related characteristics rather than fibrosis progression itself.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Metabolic dysfunction–associated steatotic liver disease (MASLD) is highly prevalent in type 2 diabetes mellitus (T2DM) and is closely linked to progressive liver fibrosis.This study evaluated the association between ultrasonographically assessed hepatic steatosis severity, non-invasive fibrosis scores, and the metabolic biomarkers ferritin, vitamin D, and magnesium in patients with T2DM-associated MASLD.
📊
Key Findings & Data:Methods: In this retrospective observational cohort study, T2DM patients with available abdominal ultrasonography were classified by steatosis grade (Grade 1–3).
💡
Conclusion & Impact:Ferritin and vitamin D were associated with fibrosis only in univariate analyses and were not independent predictors after demographic adjustment, suggesting they reflect underlying metabolic and age-related characteristics rather than fibrosis progression itself.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Tip 2 diyabetes mellitus · NAFLD · karaciğer fibrozisi

Abstract

Objective: Metabolic dysfunction–associated steatotic liver disease (MASLD) is highly prevalent in type 2 diabetes mellitus (T2DM) and is closely linked to progressive liver fibrosis.This study evaluated the association between ultrasonographically assessed hepatic steatosis severity, non-invasive fibrosis scores, and the metabolic biomarkers ferritin, vitamin D, and magnesium in patients with T2DM-associated MASLD. Methods: In this retrospective observational cohort study, T2DM patients with available abdominal ultrasonography were classified by steatosis grade (Grade 1–3). Non-invasive fibrosis scores (FIB-4, APRI, Forns index, and S-index) were calculated, and serum ferritin, 25-hydroxyvitamin D, and magnesium were analyzed. Associations were assessed by univariate and multivariable regression adjusting for age and sex. Results: FIB-4, Forns index, and S-index were significantly higher in MASLD patients than in healthy controls, but no consistent stepwise increase was observed across steatosis grades. In univariate analyses, higher ferritin was associated with higher fibrosis scores, magnesium declined with increasing severity, and vitamin D showed a weak positive correlation with FIB-4. After adjustment for age and sex, the associations of all three biomarkers lost statistical significance, and age remained the most robust determinant of fibrosis severity. Conclusion: In T2DM-associated MASLD, non-invasive fibrosis scores were elevated compared with controls without a consistent gradient across steatosis grades. Ferritin and vitamin D were associated with fibrosis only in univariate analyses and were not independent predictors after demographic adjustment, suggesting they reflect underlying metabolic and age-related characteristics rather than fibrosis progression itself.

Özet

Amaç: Metabolik disfonksiyonla ilişkili steatotik karaciğer hastalığı (MASLD), tip 2 diabetes mellitus (T2DM) hastalarında oldukça yaygındır ve progresif karaciğer fibrozisiyle yakından ilişkilidir. Bu çalışmada, T2DM ilişkili MASLD hastalarında ultrasonografi ile değerlendirilen hepatik steatoz şiddeti, non-invaziv fibrozis skorları ve ferritin, vitamin D ve magnezyum metabolik biyobelirteçleri arasındaki ilişki incelendi. Yöntem: Bu retrospektif gözlemsel kohort çalışmada, abdominal ultrasonografisi bulunan T2DM hastaları steatoz derecesine göre (Grade 1–3) sınıflandırıldı. Non-invaziv fibrozis skorları (FIB-4, APRI, Forns indeksi ve S-indeksi) hesaplandı; serum ferritin, 25-hidroksivitamin D ve magnezyum düzeyleri analiz edildi. İlişkiler, yaş ve cinsiyet için düzeltme yapılan tek değişkenli ve çok değişkenli regresyon ile değerlendirildi. Bulgular: FIB-4, Forns indeksi ve S-indeksi, MASLD hastalarında sağlıklı kontrollere kıyasla anlamlı düzeyde yüksekti; ancak steatoz dereceleri arasında tutarlı bir kademeli artış gözlenmedi. Tek değişkenli analizlerde yüksek ferritin daha yüksek fibrozis skorlarıyla ilişkiliyken, magnezyum şiddet arttıkça azaldı ve vitamin D, FIB-4 ile zayıf pozitif korelasyon gösterdi. Yaş ve cinsiyet için düzeltme yapıldığında her üç biyobelirtecin ilişkileri anlamlılığını kaybetti ve yaş, fibrozis şiddetinin en güçlü belirleyicisi olarak kaldı. Sonuç: T2DM ilişkili MASLD hastalarında non-invaziv fibrozis skorları kontrollere kıyasla yüksek bulunmuş, ancak steatoz dereceleri arasında tutarlı bir gradient saptanmamıştır. Ferritin ve vitamin D yalnızca tek değişkenli analizlerde fibrozisle ilişkili olup demografik düzeltme sonrası bağımsız belirleyici değildir; bu da onların fibrozis progresyonundan ziyade altta yatan metabolik ve yaşa bağlı özellikleri yansıttığını düşündürmektedir.

🔖

Cite This Article

Altun, G., Karatepe, B. A. (2026). RELATIONSHIP BETWEEN FIBROSIS SCORES AND FERRITIN, VITAMIN D, AND MAGNESIUM IN TYPE 2 DIABETES–RELATED HEPATIC STEATOSIS. Acta Medica Nicomedia, Cilt: 9, 1–11. https://doi.org/10.53446/actamednicomedia.1852803

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (33)

  1. Frankowski R, Kobierecki M, Wittczak A, et al. Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation. Int J Mol Sci. 2023;24(11):9677. doi:10.3390/ijms24119677
  2. Mohamed J, H. NNA, Zariyantey AH, Budin SB. Mechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation. Sultan Qaboos Univ Med J. 2016;16(2). doi:10.18295/squmj.2016.16.02.002
  3. Monserrat-Mesquida M, Quetglas‐Llabrés MM, Abbate M, et al. Oxidative Stress and Pro-Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease. Antioxidants (Basel). 2020;9(8):759. doi:10.3390/antiox9080759
  4. Lambrecht J, Tacke F. Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. Front Immunol. 2021;11. doi:10.3389/fimmu.2020.634409
  5. Zhong D, Deng S, Dong Y, et al. Dissecting causal relationships between inflammatory factors, plasma metabolites, and nonalcoholic fatty liver disease: a mediating Mendelian randomization study. Eur J Gastroenterol Hepatol. September 2025. doi:10.1097/meg.0000000000003077
  6. Wu Z, Liang Y, Zeng L, Fang J, He J. Association between dietary inflammatory index and hepatic steatosis: cross-sectional evidence from the NHANES 2007–2020. J Health Popul Nutr. 2025;44(1):295. doi:10.1186/s41043-025-01015-w
  7. Doustmohammadian A, Zamani F, Hébert JR, et al. Exploring the link between dietary inflammatory index and NAFLD through a structural equation modeling approach. J Health Popul Nutr. 2024;43(1):224. doi:10.1186/s41043-024-00721-1
  8. Liu R, Liu R, Liu M, et al. The inflammatory index and cytokines are associated with non-alcoholic fatty liver disease in type 2 diabetes mellitus. Front Med (Lausanne). 2025;12:1659998. doi:10.3389/fmed.2025.1659998
  9. Tang Y, Deng Y, Zhang G, et al. Inflammatory markers as predictors of liver fibrosis in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease. Front Endocrinol (Lausanne). 2025;16:1556646. doi:10.3389/fendo.2025.1556646
  10. Jia SD, Ye X, Kong Y, Wang Z, Wu J. Association of High-Density Lipoprotein Cholesterol-Based Inflammatory Markers With MASLD and Significant Liver Fibrosis in US Adults: Insights From NHANES 2017–2020. Clin Transl Gastroenterol. 2025;16(8). doi:10.14309/ctg.0000000000000873
  11. Arefhosseini S, Aghajani T, Tutunchi H, Ebrahimi‐Mameghani M. Association of systemic inflammatory indices with anthropometric measures, metabolic factors, and liver function in non-alcoholic fatty liver disease. Sci Rep. 2024;14(1):12829. doi:10.1038/s41598-024-63381-5
  12. Borges‐Canha M, Neves JS, SILVA MTD, et al. Waist-to-Hip Ratio and Inflammatory Parameters Are Associated with Risk of Non-Alcoholic Fatty Liver Disease in Patients with Morbid Obesity. Biomedicines. 2022;10(10):2416. doi:10.3390/biomedicines10102416
  13. Colon-Barreto B, Asuzu P, Ebenibo S, Dagogo‐Jack S. Association of Hepatic Steatosis and Fibrosis Indices With Insulin Sensitivity and Inflammation in the POP-ABC Study. J Endocr Soc. 2024;8(4). doi:10.1210/jendso/bvae020
  14. Tokarski R, Barbosa S, Pignon B, et al. Clinical and inflammatory markers associated with metabolic dysfunction-associated fatty liver disease in a cohort of individuals with chronic schizophrenia (FACE-SZ). J Psychosom Res. 2025;195:112192. doi:10.1016/j.jpsychores.2025.112192
  15. Gui Z, Chen X, Wang D, et al. Inflammatory and metabolic markers mediate the association of hepatic steatosis and fibrosis with 10-year ASCVD risk. Ann Med. 2025;57(1):2486594. doi:10.1080/07853890.2025.2486594
  16. Gao X, Zhu C, Zhu W, Wang L. Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes. Biomed Rep. 2024;22(2):26. doi:10.3892/br.2024.1904
  17. Saucedo L, Pfister IB, Schild C, Garweg JG. Association of inflammation-related markers and diabetic retinopathy severity in the aqueous humor, but not serum of type 2 diabetic patients. PLoS One. 2023;18(10). doi:10.1371/journal.pone.0293139
  18. Chen M, Guo C, Ouyang K, Liu N. Diagnostic role of the fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score as a noninvasive tool for liver fibrosis scoring. Medicine (Baltimore). 2024;103(43). doi:10.1097/md.0000000000040214
  19. Wai C, Greenson JK, Fontana RJ, et al. A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C. Hepatology. 2003;38(2):518. doi:10.1053/jhep.2003.50346
  20. Boursier J, Bacq Y, Halfon P, et al. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2008;21(1):28. doi:10.1097/meg.0b013e32830cebd7
  21. Zhou K, Gao C, Zhao Y, et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2010;25(9):1569. doi:10.1111/j.1440-1746.2010.06383.x
  22. Hamada Y, Hirano E. Regulation of Iron Metabolism in NAFLD/NASH. In: IntechOpen eBooks. IntechOpen; 2022. doi:10.5772/intechopen.107221
  23. Gao H, Jin Z, Bandyopadhyay G, et al. Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis. Cell Metab. 2022;34(8):1201. doi:10.1016/j.cmet.2022.07.006
  24. Ruddell RG, Hoang-Le D, Barwood JM, et al. Ferritin functions as a proinflammatory cytokine via iron‐independent protein kinase C zeta/nuclear factor kappaB–regulated signaling in rat hepatic stellate cells†. Hepatology. 2008;49(3):887. doi:10.1002/hep.22716
  25. Abouzeed HS, Eldin LB, Masry SME, et al. Stoss therapy versus weekly regimen of vitamin D in children with chronic liver disease: a randomized pilot study. Egypt Liver J. 2023;13(1). doi:10.1186/s43066-023-00249-9
  26. Jiang R, Zhou Y, Han L, Hong Z. Serum vitamin D is associated with ultrasound-defined hepatic fibrosis. Clin Res Hepatol Gastroenterol. 2023;47(10):102228. doi:10.1016/j.clinre.2023.102228
  27. Kubesch A, Quenstedt L, Saleh M, et al. Vitamin D deficiency is associated with hepatic decompensation and inflammation in patients with liver cirrhosis: A prospective cohort study. PLoS One. 2018;13(11). doi:10.1371/journal.pone.0207162
  28. Arancibia‐Hernández YL, Hernández‐Cruz EY, Pedraza-Chaverrı́ J. Magnesium (Mg2+) Deficiency, Not Well-Recognized Non-Infectious Pandemic: Origin and Consequence of Chronic Inflammatory and Oxidative Stress-Associated Diseases. Cell Physiol Biochem. 2022;57:1. doi:10.33594/000000603
  29. Al-Maqbali JS, Harasi SA, Mamary QA, et al. Ionized and total magnesium levels and health outcomes in patients with type 2 diabetes mellitus. Sci Rep. 2025;15(1):4329. doi:10.1038/s41598-025-88081-6
  30. Rinella ME, Neuschwander-Tetri BA, Siddiqi MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323
  31. Kang YW, Baek YH, Moon SY. Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. Diagnostics (Basel). 2024;14(22):2517. doi:10.3390/diagnostics14222517
  32. Tian M, Huang X, Li M, et al. Ferroptosis in diabetic cardiomyopathy: from its mechanisms to therapeutic strategies. Front Endocrinol (Lausanne). 2024;15. doi:10.3389/fendo.2024.1421838
  33. Winiarska A, Knysak M, Nabrdalik K, Gumprecht J, Stompór T. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists. Int J Mol Sci. 2021;22(19):10822. doi:10.3390/ijms221910822